TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Two Strategies for Setting Positive End-Expiratory Pressure in Acute Lung Injury/ Acute Respiratory Distress Syndrome (ExPress Study).
Brief Summary: The aim of this multicenter randomized controlled trial is to compare the impact on mortality of patients mechanically ventilated for acute lung injury or acute respiratory distress syndrome of two strategies for setting end-expiratory pressure.


Options:
A: Arm Label: Albuterol Sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Albuterol Sulfate, Procedure: Mini-Bronchoalveolar Lavage (BAL) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Mini-Bronchoalveolar Lavage (BAL), Drug: Placebo | Intervention Type: DRUG; Name: Albuterol Sulfate; Assigned to Arm(s): Albuterol Sulfate | Intervention Type: PROCEDURE; Name: Mini-Bronchoalveolar Lavage (BAL); Assigned to Arm(s): Albuterol Sulfate, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: PROCEDURE; Name: Control Ventilation Strategy; Assigned to Arm(s): N/A
C: Arm Label: EPVent; Type: EXPERIMENTAL; Interventions: Procedure: Placement of an esophageal balloon measurements, Other: Transpulmonary pressure-directed ventilation (EPVent) | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Placement of an esophageal balloon measurements, Other: Low tidal volume ventilation | Intervention Type: PROCEDURE; Name: Placement of an esophageal balloon measurements; Assigned to Arm(s): Control, EPVent | Intervention Type: OTHER; Name: Low tidal volume ventilation; Assigned to Arm(s): Control | Intervention Type: OTHER; Name: Transpulmonary pressure-directed ventilation (EPVent); Assigned to Arm(s): EPVent
D: Arm Label: Minimal alveolar distension; Type: ACTIVE_COMPARATOR; Interventions: Device: Setting of positive end-expiratory pressure | Arm Label: Maximal alveolar distension; Type: EXPERIMENTAL; Interventions: Device: Setting of positive end-expiratory pressure | Intervention Type: DEVICE; Name: Setting of positive end-expiratory pressure; Assigned to Arm(s): Maximal alveolar distension, Minimal alveolar distension

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Psychoeducation Versus Cognitive-Behavioral Therapy in Bipolar Disorder
Brief Summary: To examine the impact of cognitive-behavioural therapy on both the episodic and functional outcome of bipolar disorder, in combination with pharmacotherapy.

Primary Hypothesis is twofold:

1. Cognitive Behavioural Therapy will reduce the total symptom burden, as measured both by percentage of time spent ill (both syndromic and subsyndromal) and number of episodes, as compared to psychoeducation
2. Cognitive behavioural therapy will reduce social and occupational disability to a greater extent than psychoeducation.


Options:
A: Intervention Type: DRUG; Name: lamotrigine; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Psychoeduction; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive-Behavioral Therapy; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: BW430C(lamotrigine); Type: ACTIVE_COMPARATOR; Interventions: Drug: lamotrigine | Intervention Type: DRUG; Name: lamotrigine; Assigned to Arm(s): BW430C(lamotrigine) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Arm 1; Type: OTHER; Interventions: Drug: lamotrigine | Intervention Type: DRUG; Name: lamotrigine; Assigned to Arm(s): Arm 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients
Brief Summary: Patients with epithelial ovarian cancer, fallopian tube or peritoneal cancer who receive surgical cytoreduction and platinum/taxane containing chemotherapy have a significant chance of entering complete clinical remission but about 70% will eventually relapse. Many patients respond to additional cytotoxic treatment with partial or complete responses, yet approximately 100% of these patients will ultimately progress. Novel consolidation strategies following treatment for recurrent disease are needed and an immunologic approach is an attractive option.EpCAM is expressed in a large number of epithelial ovarian cancer, fallopian tube or peritoneal cancer tissues. Thus targeting these cancers with an anti-EpCAM antibody is a promising innovative therapeutic approach.


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: NY-ESO-1 OLP4 | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: NY-ESO-1 OLP4 + Montanide | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Biological: NY-ESO-1 OLP4 + Montanide + Poly-ICLC | Intervention Type: BIOLOGICAL; Name: NY-ESO-1 OLP4; Assigned to Arm(s): Cohort 1 | Intervention Type: BIOLOGICAL; Name: NY-ESO-1 OLP4 + Montanide; Assigned to Arm(s): Cohort 2 | Intervention Type: BIOLOGICAL; Name: NY-ESO-1 OLP4 + Montanide + Poly-ICLC; Assigned to Arm(s): Cohort 3
B: Intervention Type: BIOLOGICAL; Name: CDX-1401 in combination with Resiquimod and/or Poly-ICLC; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: CDX-1401; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Resiquimod; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: poly-ICLC; Assigned to Arm(s): N/A
C: Arm Label: Abagovomab; Type: EXPERIMENTAL; Interventions: Biological: Abagovomab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Abagovomab; Assigned to Arm(s): Abagovomab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: BIOLOGICAL; Name: anti-EpCAM x anti-CD3 (removab); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ResQ Trial: Comparison of Standard CPR Alone Versus Active Compression Decompression CPR Plus an ITD on Survival From Out-of-Hospital Cardiac Arrest
Brief Summary: The purpose of this study is to determine whether performing active compression decompression cardiopulmonary resuscitation (ACD-CPR) with an impedance threshold device (ITD) compared to conventional standard cardiopulmonary resuscitation (S-CPR) will impact the neurologic recovery and survival to hospital discharge following out-of-hospital cardiac arrest.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: AutoPulse | Arm Label: 2; Type: OTHER; Interventions: Other: Manual | Intervention Type: DEVICE; Name: AutoPulse; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Manual; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Use of an impedance threshold device (ITD) during the performance of active compression decompression CPR (ACD-CPR) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard cardiopulmonary resuscitation (S-CPR) | Intervention Type: DEVICE; Name: Use of an impedance threshold device (ITD) during the performance of active compression decompression CPR (ACD-CPR); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Standard cardiopulmonary resuscitation (S-CPR); Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: AutoPulse | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual CPR | Intervention Type: DEVICE; Name: AutoPulse; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Manual CPR; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Impedance Threshold Device (ITD) | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: Sham ITD | Arm Label: 3; Type: OTHER; Interventions: Other: Analyze early | Arm Label: 4; Type: OTHER; Interventions: Other: Analyze later | Intervention Type: DEVICE; Name: Impedance Threshold Device (ITD); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Sham ITD; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Analyze early; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Analyze later; Assigned to Arm(s): 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison Expectant With Immediate Medical Management for the Evacuation of the no Evolutionary Pregnancies Before 13 GW
Brief Summary: Compared the interest of one week expectancy vs immediate medical treatment in the taking care of the evacuation of the no evolutionary pregnancies before 13 GW.


Options:
A: Arm Label: hospital- based vaginal misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: vaginal misoprostol | Arm Label: extended low dose oral misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: buccal/sublingual misoprostol | Intervention Type: DRUG; Name: vaginal misoprostol; Assigned to Arm(s): hospital- based vaginal misoprostol | Intervention Type: DRUG; Name: buccal/sublingual misoprostol; Assigned to Arm(s): extended low dose oral misoprostol
B: Arm Label: extra amniotic misoprostol; Type: EXPERIMENTAL; Interventions: Procedure: termination of second trimester pregnancy | Arm Label: vaginal misoprostol; Type: EXPERIMENTAL; Interventions: Procedure: termination of second trimester pregnancy | Intervention Type: PROCEDURE; Name: termination of second trimester pregnancy; Assigned to Arm(s): extra amniotic misoprostol, vaginal misoprostol
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1
D: Arm Label: surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): surgery

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison Expectant With Immediate Medical Management for the Evacuation of the no Evolutionary Pregnancies Before 13 GW
Brief Summary: Compared the interest of one week expectancy vs immediate medical treatment in the taking care of the evacuation of the no evolutionary pregnancies before 13 GW.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1
B: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: 600 mcg misoprostol | Arm Label: Surgical treatment; Type: OTHER; Interventions: Procedure: Surgical treatment | Intervention Type: DRUG; Name: 600 mcg misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: Surgical treatment; Assigned to Arm(s): Surgical treatment
C: Arm Label: Single dose group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Repeated dose group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Repeated dose group, Single dose group
D: Arm Label: pitocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: mifepristone and oxytocin | Arm Label: misopristol; Type: ACTIVE_COMPARATOR; Interventions: Drug: mifepristone and misopristol | Intervention Type: DRUG; Name: mifepristone and misopristol; Assigned to Arm(s): misopristol | Intervention Type: DRUG; Name: mifepristone and oxytocin; Assigned to Arm(s): pitocin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison Expectant With Immediate Medical Management for the Evacuation of the no Evolutionary Pregnancies Before 13 GW
Brief Summary: Compared the interest of one week expectancy vs immediate medical treatment in the taking care of the evacuation of the no evolutionary pregnancies before 13 GW.


Options:
A: Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1
C: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: 600 mcg misoprostol | Arm Label: Surgical treatment; Type: OTHER; Interventions: Procedure: Surgical treatment | Intervention Type: DRUG; Name: 600 mcg misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: Surgical treatment; Assigned to Arm(s): Surgical treatment
D: Arm Label: surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): surgery

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison Expectant With Immediate Medical Management for the Evacuation of the no Evolutionary Pregnancies Before 13 GW
Brief Summary: Compared the interest of one week expectancy vs immediate medical treatment in the taking care of the evacuation of the no evolutionary pregnancies before 13 GW.


Options:
A: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: 600 mcg misoprostol | Arm Label: Surgical treatment; Type: OTHER; Interventions: Procedure: Surgical treatment | Intervention Type: DRUG; Name: 600 mcg misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: Surgical treatment; Assigned to Arm(s): Surgical treatment
B: Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): N/A
C: Arm Label: surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): surgery
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison Expectant With Immediate Medical Management for the Evacuation of the no Evolutionary Pregnancies Before 13 GW
Brief Summary: Compared the interest of one week expectancy vs immediate medical treatment in the taking care of the evacuation of the no evolutionary pregnancies before 13 GW.


Options:
A: Arm Label: midwife; Type: EXPERIMENTAL; Interventions: Other: Midwife | Arm Label: Physician; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Midwife; Assigned to Arm(s): midwife
B: Arm Label: Misoprostol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Misoprostol and Mifepristone; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone, Drug: Misoprostol | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): Misoprostol and Mifepristone | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, Misoprostol and Mifepristone
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MIFEPRISTONE 200 mg and misoprostol 400 µg | Intervention Type: DRUG; Name: MIFEPRISTONE 200 mg and misoprostol 400 µg; Assigned to Arm(s): 1
D: Arm Label: Midlevel provider; Type: OTHER; Interventions: Other: Type of provider | Arm Label: Physician arm; Type: OTHER; Interventions: Other: Type of provider | Intervention Type: OTHER; Name: Type of provider; Assigned to Arm(s): Midlevel provider, Physician arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Endarterectomy Versus Angioplasty in Patients With Severe Symptomatic Carotid Stenosis
Brief Summary: The purpose of this study is to evaluate whether carotid angioplasty with stent (CAS) is as safe and effective as carotid surgery in regards to:

1. the risk of stroke and death within 30 days of the procedure;
2. the long-term risk of ipsilateral carotid territory stroke, in patients with recently symptomatic, severe carotid stenosis suitable for both CAS and carotid endarterectomy.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Carotid angioplasty and stenting with cerebral protection | Intervention Type: DEVICE; Name: Carotid angioplasty and stenting with cerebral protection; Assigned to Arm(s): 1
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Carotid artery stenting with filter (interventional) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid artery endarterectomy (surgical) | Intervention Type: DEVICE; Name: Carotid artery stenting with filter (interventional); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Carotid artery endarterectomy (surgical); Assigned to Arm(s): 2
C: Arm Label: CEA with sonolysis; Type: EXPERIMENTAL; Interventions: Procedure: sonolysis, Procedure: endarterectomy | Arm Label: CEA without sonolysis; Type: PLACEBO_COMPARATOR; Interventions: Procedure: endarterectomy | Arm Label: carotid stenting with sonolysis; Type: EXPERIMENTAL; Interventions: Procedure: sonolysis, Procedure: carotid stenting | Arm Label: carotid stenting without sonolysis; Type: PLACEBO_COMPARATOR; Interventions: Procedure: carotid stenting | Intervention Type: PROCEDURE; Name: sonolysis; Assigned to Arm(s): CEA with sonolysis, carotid stenting with sonolysis | Intervention Type: PROCEDURE; Name: endarterectomy; Assigned to Arm(s): CEA with sonolysis, CEA without sonolysis | Intervention Type: PROCEDURE; Name: carotid stenting; Assigned to Arm(s): carotid stenting with sonolysis, carotid stenting without sonolysis
D: Arm Label: Carotid Endarterectomy (CEA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid endarterectomy (CEA) | Arm Label: Carotid Stenting (CAS); Type: ACTIVE_COMPARATOR; Interventions: Device: Carotid Stenting (CAS) | Arm Label: Intensive Medical Management - no CEA; Type: EXPERIMENTAL; Interventions: Other: Intensive Medical Management - no CEA | Arm Label: Intensive Medical Management - no CAS; Type: EXPERIMENTAL; Interventions: Other: Intensive Medical Management - no CAS | Intervention Type: PROCEDURE; Name: Carotid endarterectomy (CEA); Assigned to Arm(s): Carotid Endarterectomy (CEA) | Intervention Type: DEVICE; Name: Carotid Stenting (CAS); Assigned to Arm(s): Carotid Stenting (CAS) | Intervention Type: OTHER; Name: Intensive Medical Management - no CEA; Assigned to Arm(s): Intensive Medical Management - no CEA | Intervention Type: OTHER; Name: Intensive Medical Management - no CAS; Assigned to Arm(s): Intensive Medical Management - no CAS

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Raloxifene Hydrochloride or Placebo in Postmenopausal Women at Risk for Major Coronary Events
Brief Summary: The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.


Options:
A: Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: raloxifene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
D: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tamoxifen | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: Raloxifene | Intervention Type: DRUG; Name: Raloxifene; Assigned to Arm(s): Group 2 | Intervention Type: DRUG; Name: Tamoxifen; Assigned to Arm(s): Group 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Raloxifene Hydrochloride or Placebo in Postmenopausal Women at Risk for Major Coronary Events
Brief Summary: The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.


Options:
A: Intervention Type: DRUG; Name: alendronate (Fosamax); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alendronate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Alendronate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: raloxifene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
D: Arm Label: Alendronate/Alendronate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alendronate, Drug: Placebo to Romosozumab | Arm Label: Romosozumab/Alendronate; Type: EXPERIMENTAL; Interventions: Biological: Romosozumab, Drug: Alendronate, Drug: Placebo to Alendronate | Intervention Type: BIOLOGICAL; Name: Romosozumab; Assigned to Arm(s): Romosozumab/Alendronate | Intervention Type: DRUG; Name: Alendronate; Assigned to Arm(s): Alendronate/Alendronate, Romosozumab/Alendronate | Intervention Type: DRUG; Name: Placebo to Romosozumab; Assigned to Arm(s): Alendronate/Alendronate | Intervention Type: DRUG; Name: Placebo to Alendronate; Assigned to Arm(s): Romosozumab/Alendronate

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dose Response Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome
Brief Summary: To assess the efficacy of Duloxetine compared with placebo in the treatment of pain in patients with Fibromyalgia syndrome, with or without major depressive disorder.


Options:
A: Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Milnacipran | Arm Label: Milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Milnacipran | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Milnacipran, Sugar pill
B: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Placebo | Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin, Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Duloxetine, Pregabalin
C: Arm Label: Duloxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral tablet | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo oral tablet; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A

Answer: D